Quest Diagnostics Inc vs Indonesia Energy Corporation Limited — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Indonesia Energy Corporation Limited trades at $2.94 (market cap $45.24M). The key difference: Quest Diagnostics Inc is far larger — about 504× Indonesia Energy Corporation Limited's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals.
| DGX | INDO | |
|---|---|---|
Market Cap | $22.80B | $45.24M |
Sector | Health | Energy |
52-Week High | $216.02 | $6.74 |
52-Week Low | $166.42 | $2.49 |
Enterprise Value | $28.82B | $40.61M |
Dividend Yield | 1.67% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
INDO trades at $3.00, up 9.49% today, with a bullish technical signal from moving averages and oscillators. The company reported a net loss of $5 million on $2 million revenue in 2025, with negative profit margins. Recent news highlights operational progress, including the commencement of drilling at the Kruh Block. Analyst consensus is unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of new well operations to drive revenue growth and reduce losses. Key risks include sustained negative profitability and operational challenges in oil exploration. Upside potential exists if production targets are met, but investors face significant financial and execution risks.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →